MedTrace Logo

Omacor and Cardiovascular Risk Factors in HIV Patients on HAART Treatment

NCT00296153 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2008-03-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of Omacor 4g/day on blood lipid parameters and on the function and stiffness of blood vessels in HIV infected patients on Antiretroviral Therapy (HAART)

Conditions

  • Human Immunodeficiency Virus
  • Ischemic Heart Disease

Interventions

DRUG

Omega-3-acid ethyl esters 90

Omacor capsule 1000mg x 4 per day. Duration 12 weeks

Sponsors & Collaborators

  • Aalborg University Hospital

    collaborator OTHER

  • Pronova BioPharma

    lead INDUSTRY

Principal Investigators

  • Jeppe H. Christensen, PhD · Aalborg Hospital, Department of Nephrology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2006-11-30
Completion
2007-10-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00296153 on ClinicalTrials.gov